by: Parent Project Muscular DystrophyPPMD was joined by Edgewise Therapeutics for a community webinar on October 19, 2022. Edgewise’s Chief Scientific Officer and Chief Medical Officer discussed the clinical development program for EDG-5506, a myosin modulator, in Becker and Duchenne muscular dystrophies. The webinar also highlighted the mechanism of action, results from the ongoing open-label ARCH study in adults with Becker muscular dystrophy, and upcoming trials.
